[R ± BEACOP for Treating Newly Diagnosed, Moderate and High Risk Diffuse Large B Cell Lymphoma Patients].
To evaluate the efficacy and safety of R ± BEACOP protocol on newly diagnosed patients with moderate and high risk diffuse large B-cell lymphoma (DLBCL). The clinical data of 19 newly diagnosed patients with moderate and high risk DLBCL received at least 2 cycles of R ± BEACOP protocol during 2011 to 2014 were collected, their therapeutic efficacy and side effects were evaluated by retrospective analysis. The overall response rate of 19 assessable patients was 94.7%, including 5 patients (26.3%) in complete remission (CR) and 13 patients (68.4%) in partial remission (PR). The major toxicity was hematologic toxicity and the incidence of grade III-IV hematologic toxicity was 73.7%. Other toxicities were mild and no treatment-related death occurred. R ± BEACOP protocol is a effective and safe protocol for the patients with DLBCL which is worth further multicenter prospectively studying in china.